This is a past event. Its details are archived for historical purposes.
The contact information may no longer be valid.
Please visit our current events listings to look for similar events by title, location, or venue.
Thursday, September 12, 2013 at 4:15pm to 5:15pm
Abstract
Convection—enhanced delivery (CED) was conceived by a group led by Oldfield, then at the NIH, to allow biologic agents to distribute in brain tissue past the blood—brain barrier (BBB) by direct infusion into the brain. We have been working in interrelated areas aimed at improving therapeutic CED. This talk will be on one of these: characterizing and modeling cytoarchitectural and other determinants of transport of particulates in brain, allowing insights into manipulating infusion procedures (specific to disease and therapeutic agent) to maximize the effective delivery of therapies. After an introduction to the phenomena in question, we discuss how we solve the equations that account for the phenomena, and how we may obtain the input parameters needed for the calculation to apply to an individual, principally from MRI. Finally, we review the status of the experimental data in checking the predictions. Experiments are being conducted in gels, pigs, dogs, monkeys, and humans.
There are other applications and a detailed model will open the search space for new attacks on such problems. In conclusion we mention two related to brain cancer therapeutics and disease management.
Biography
Dr. Raghavan founded Therataxis, LLC, devoted to research and development in guiding therapy to targets in tissue, primarily the brain. Prior experience includes Vice President at Image-guided Neurologics, research professor in the computer science and radiology departments at Johns Hopkins University, and the founder and director of the Center for Information-enhanced Medicine (CieMed) at the National University of Singapore. His doctorate is in the physics of magnetism at the University of Wisconsin. Since then, he has contributed to the development of imaging sensor materials, image analysis integrating models and data, parallel computing, and biomedical simulations, including brain physiology and drug transport. His current research interests are focused upon the simulation and control of molecular and cell therapies and on pattern formation during tissue and organ growth. Dr. Raghavan has published over 110 papers and is inventor on over 20 patents and patent applications.
Raghu Raghavan
Therataxis, LLC.
No recent activity